
When Buy-And-Hold Becomes A Retirement-Sapping Taxable Event
While there's no evidence that Albert Einstein uttered the quip long associated with him about compound returns as the '8th Wonder of the World,' it's not unreasonable to imagine the genius wit saying something just like that. When it comes to savings, compounding has wondrous qualities that become magical over time.
That's why the patient investor can combine prudence with time to become a well-to-do retiree. As investor Barry Ritholtz pointed out in his recently released book How Not To Invest, compounding easily papers over a multitude of investment errors, including a propensity to buy at the top of every market. What Ritholtz found via empirical study is that over long stretches of time, the returns enjoyed by the investor prone to buy just ahead of market declines and corrections does almost as well as the proverbial unicorn who routinely buys at market lows. Such is the genius of buying and holding through market downs and ups.
These truths rate prominent thought in consideration of how capital gains achieved by mutual funds are presently taxed. While the funds themselves don't pay taxes on gains realized through sales, the individual investors in their funds do. That's the why behind the title of this opinion piece.
Even when mutual fund investors intend to hold their shares in the fund for the long-term, they pay annual capital gains taxes as though they're actively trading. Explained more plainly, gains realized by the fund managers are paid for in taxes by the smaller, frequently retail investors in the fund. Stop and think about this.
On its face, the tax shifting that this enables exists as a penalty placed on small investors who wisely outsource their stock-picking to others. Outsourcing is crucial precisely because investing is best left to the experts. To invest for oneself is like cutting one's own hair.
At the same time, what are investors supposed to do when doing the right thing comes at a cost? Compounding once again reveals magical qualities when matched with time, but if the returns are going to be compromised by taxable event-style trading that is paid for by the retail investor, then the incentive is to still buy and hold, albeit in cutting one's own hair fashion.
Thankfully there's a potential fix working its way through Congress. Reps. Beth Van Duyne (R-TX) and Terri Sewell (D-AL) have introduced the Generating Retirement Ownership Through Long-Term Holding (GROWTH) Act to correct what saps the genius of patient, buy-and-hold retirement saving. The GROWTH Act will spare buy-and-hold mutual fund investors annual taxes run up by fund managers, and will instead defer the taxation on realized gains to when the retail investor ultimately sells the shares in the fund. So, while there shouldn't be taxation of any kind on capital gains, the GROWTH Act at the very least corrects a retirement-sapping injustice that neuters the genius of compounding through annual taxation gains realized by fund managers, as opposed to fund shareholders.
Enormous effort goes into planning for and saving for retirement. What a mistake to penalize prudence with a tax levied on retirement savers acting with extraordinary prudence. Let's erase a very real bug in the tax code that so substantially chips away at the genius of patient, long-term retirement saving.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Congresswoman Files Hundreds Of Stock Trades Late, Including Palantir Stock Up Over 600%
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Efforts to ban members of Congress from buying and selling stocks could continue to rise with several recent disclosures violating the STOCK Act. A new filing by a member of Congress lists hundreds of trades since March 2024. Here's the latest. What Happened: One of the hottest stocks for members of Congress to buy in 2025 has been Palantir Technologies (NASDAQ:PLTR), a company that has won numerous government contracts and may pose a conflict of interest for members serving on government committees who invest in the stock. Congresswoman Lisa McClain (R-Mich.) previously served on the Committee on Armed Services and the Subcommittee on Cyber, Information Technologies, and Innovation. Trending: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — The Congresswoman recently disclosed hundreds of stock trades in an Aug. 13 filing. While some of the hundreds of stock purchases and sales happened in the months of August and July 2025, many of the trades were dated back to periods in 2024. The purchases in the filing went all the way back to March 2024, as reported by the Benzinga Government Trades page. Among the notable transactions were multiple trades involving Palantir stock. Here are five trades disclosed in the filing and the highest price for PLTR stock on that particular day: June 6, 2024: Bought $15,000 to $50,000 in PLTR stock, stock high $23.95 August 14, 2024: Bought $15,000 to $50,000 in PLTR stock, stock high $31.37 October 23, 2024: Sold $50,000 to $100,000 in PLTR stock, stock high $43.68 November 7, 2024: Bought $100,000 to $250,000 in PLTR stock, stock high $56.47 June 17, 2025: Bought $1,000 to $15,000 in PLTR stock, stock high $141.69 Palantir stock trades at $177.17 at the time of writing, significantly higher than the prices above. In fact, Palantir stock is up 639.7% from the first purchase in June 2024 based on the highest price point of the day. The stock is also up at least 464.8% from the August 2024 purchase price and up 213.7% from the November 2024 price. It is unknown whether McClain sold the entire positions bought in June and August 2024 in the October 2024 sale, which was reported at between $50,000 and $100,000. Palantir stock is also up 25% from the latest purchase in June 2025. Benzinga reached out for comment and did not hear to a report from the Detroit News, the trades in the filing were conducted by McClain's husband Mike. "She promptly filed the necessary paperwork immediately after being made aware of the transactions made in managed accounts and remains committed to transparency and adherence to all House financial disclosure rules and regulations," spokesman Mason Devers told the Detroit News. The transactions were reported outside the 45-day disclosure window, which could result in fines of $200 for the Congresswoman. What's Next: McClain's late filings come after Sen. Josh Hawley (R-Mo.) introduced the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act, based on the first letter of each of the main words. The name targets Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.). The bill made its way out of committee and could come before Congress for a vote. Benzinga recently polled readers to gauge their stance on a potential ban on Congress members trading. 'Should members of Congress be allowed to buy and sell stocks, options and ETFs?' Benzinga asked. These were the results: They should not be allowed to trade stocks, options or ETFs: 43% They should be allowed to trade as long as they report within 24 hours: 24% They should only be allowed to trade ETFs and mutual funds: 14% They should be allowed to trade as long as they report in 45 days: 11% They should only be allowed to trade stocks: 8% The poll found that 43% of readers support an outright ban on members of Congress trading stocks, options, or ETFs. Eleven percent voted to leave the current rules unchanged, with a 45-day disclosure window. Read Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo: Shutterstock This article Congresswoman Files Hundreds Of Stock Trades Late, Including Palantir Stock Up Over 600% originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wall Street Journal
3 hours ago
- Wall Street Journal
Intel Shares Drop as U.S. Considers Acquiring 10% Stake in Chip Maker
An Intel booth at a computing conference in Taipei last year. (I-Hwa Cheng/Agence France-Presse/Getty Images)
Yahoo
3 hours ago
- Yahoo
Asian Growth Companies Insiders Own With Up To 78% Earnings Growth
As global markets navigate a landscape marked by inflation concerns and shifting trade dynamics, Asia's economic environment presents unique growth opportunities. In this context, companies with high insider ownership can offer valuable insights into potential earnings growth, as insiders often have a deep understanding of their business prospects and confidence in the company's future. Top 10 Growth Companies With High Insider Ownership In Asia Name Insider Ownership Earnings Growth Zhejiang Leapmotor Technology (SEHK:9863) 15.6% 60.7% Synspective (TSE:290A) 12.8% 49.7% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 25.8% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 24.3% Novoray (SHSE:688300) 23.6% 28.2% M31 Technology (TPEX:6643) 30.7% 96.8% Laopu Gold (SEHK:6181) 35.5% 43% Gold Circuit Electronics (TWSE:2368) 31.4% 35.2% Fulin Precision (SZSE:300432) 12.8% 43.7% Click here to see the full list of 592 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Underneath we present a selection of stocks filtered out by our screen. Jiangxi Rimag Group Simply Wall St Growth Rating: ★★★★★☆ Overview: Jiangxi Rimag Group Co., Ltd. operates medical imaging centers in China and has a market cap of HK$7.26 billion. Operations: The company generates revenue from its medical labs and research segment, amounting to CN¥760.59 million. Insider Ownership: 10.7% Earnings Growth Forecast: 78.5% p.a. Jiangxi Rimag Group demonstrates strong growth potential with forecasted revenue growth of 22.3% per year, outpacing the Hong Kong market. Insider confidence is evident as more shares were bought than sold recently, and the company trades at a significant discount to its estimated fair value. Recent earnings guidance suggests substantial profit increases due to higher customer numbers and reduced expenses, while an active share repurchase program aims to enhance shareholder value further. Unlock comprehensive insights into our analysis of Jiangxi Rimag Group stock in this growth report. Upon reviewing our latest valuation report, Jiangxi Rimag Group's share price might be too optimistic. Bozhon Precision Industry TechnologyLtd Simply Wall St Growth Rating: ★★★★☆☆ Overview: Bozhon Precision Industry Technology Co., Ltd. (SHSE:688097) operates in the precision machinery industry and has a market cap of CN¥14.97 billion. Operations: The company's revenue from Industrial Automation & Controls amounts to CN¥4.95 billion. Insider Ownership: 29.9% Earnings Growth Forecast: 25.6% p.a. Bozhon Precision Industry Technology Ltd. shows promising growth prospects with earnings expected to rise significantly at 25.63% annually, surpassing the CN market's average. Despite trading at a substantial discount to its estimated fair value, concerns arise from large one-off items impacting financial results and a low forecasted return on equity of 12.3%. Recent transactions include selling machinery equipment worth RMB 224.74 million to Hon Hai Precision Industry Co., Ltd., reflecting strategic asset management activities. Delve into the full analysis future growth report here for a deeper understanding of Bozhon Precision Industry TechnologyLtd. Our valuation report here indicates Bozhon Precision Industry TechnologyLtd may be undervalued. Beijing Sun-Novo Pharmaceutical Research Simply Wall St Growth Rating: ★★★★★☆ Overview: Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is a contract research company focused on drug research and development in China, with a market cap of CN¥8.38 billion. Operations: I'm sorry, but it seems there is no specific revenue segment information provided in the text you shared. If you have additional details or data on their revenue segments, please provide them so I can assist you further. Insider Ownership: 35.3% Earnings Growth Forecast: 29.6% p.a. Beijing Sun-Novo Pharmaceutical Research anticipates robust earnings growth of 29.6% annually, outpacing the CN market average. Despite a volatile share price and declining profit margins from 22% to 12.7%, the company maintains strong revenue growth projections at 18.2% per year, exceeding market expectations. With no recent insider trading activity reported, investors should consider both its high return on equity forecast of 23.4% and current financial volatility when evaluating potential opportunities. Click to explore a detailed breakdown of our findings in Beijing Sun-Novo Pharmaceutical Research's earnings growth report. Our valuation report unveils the possibility Beijing Sun-Novo Pharmaceutical Research's shares may be trading at a premium. Next Steps Gain an insight into the universe of 592 Fast Growing Asian Companies With High Insider Ownership by clicking here. Interested In Other Possibilities? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:2522 SHSE:688097 and SHSE:688621. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data